H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Matinas BioPharma (MTNB – Research Report) today and set a price target of $3.00. The company’s shares closed yesterday at $0.85.
Fein covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals Inc, ACADIA Pharmaceuticals, and Vertex Pharmaceuticals. According to TipRanks, Fein has an average return of -6.8% and a 39.78% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Matinas BioPharma with a $3.00 average price target.
See the top stocks recommended by analysts >>
MTNB market cap is currently $183.6M and has a P/E ratio of -7.19.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling the delivery of life-changing medicines using its LNC platform technology. The company’s proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins, and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. Its anti-fungal product candidate, MAT2203, delivers broad-spectrum fungicidal agent, amphotericin B; and is being developed to prevent invasive fungal infections in patients with acute lymphoblastic leukemia. The company was founded in May 2013 and is headquartered in Bedminster, NJ.
Read More on MTNB:
- H.C. Wainwright Sticks to Their Hold Rating for Onconova Therapeutics (ONTX)
- H.C. Wainwright Keeps Their Buy Rating on iTeos Therapeutics (ITOS)
- H.C. Wainwright Keeps Their Buy Rating on Dice Therapeutics (DICE)
- H.C. Wainwright Remains a Buy on Nkarta (NKTX)
- H.C. Wainwright Sticks to Their Buy Rating for Janux Therapeutics Inc (JANX)
